| Emily Hull Schmidt, | |
|
155 N Oakdale Ave Ste 300, Salina, KS 67401-3001 | |
| (785) 452-6050 | |
| Not Available |
| Full Name | Emily Hull Schmidt |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 155 N Oakdale Ave Ste 300, Salina, Kansas |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104452390 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 2212 (Kansas) | Primary |
| Provider Name | Salina Regional Health Center Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1619952785 PECOS PAC ID: 0446168215 Enrollment ID: O20040130000800 |
News Archive
For decades, American Baby Boomers have been characterized as a bloc of people who think and act as one monolithic generation. However, recent data from the MetLife Mature Market Institute®, show that Young, Middle and Older Boomers grew up during disparate "eras" and are now at different stages in their lives. They should, perhaps, be treated as separate demographic groups.
While childhood cancer is rare (adult malignancies after 20 years are 20-30 times more common in general) it remains a major cause of death by disease in children. 15,700 children are diagnosed with cancer each year in the USA.
Onyx Pharmaceuticals, Inc. today announced updated interim results of the Phase 1b dose-escalation trial, known as the 006 study, evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed and/or refractory myeloma. These data are being presented today at the 46th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
BioCardia, Inc., focused on regenerative biologic therapies for cardiovascular disease, today announced positive results from a Phase 1/2 heart failure trial using the Company's Helical Infusion System, comprising the Helical Infusion System Catheter and Morph Vascular Access Catheter, to deliver allogeneic, or "off-the-shelf," and autologous, or from the treated patient, mesenchymal (adult) stem cells (MSCs) via transendocardial injection.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Emily Hull Schmidt, 155 N Oakdale Ave Ste 300, Salina, KS 67401-3001 Ph: (785) 452-6050 | Emily Hull Schmidt, 155 N Oakdale Ave Ste 300, Salina, KS 67401-3001 Ph: (785) 452-6050 |
News Archive
For decades, American Baby Boomers have been characterized as a bloc of people who think and act as one monolithic generation. However, recent data from the MetLife Mature Market Institute®, show that Young, Middle and Older Boomers grew up during disparate "eras" and are now at different stages in their lives. They should, perhaps, be treated as separate demographic groups.
While childhood cancer is rare (adult malignancies after 20 years are 20-30 times more common in general) it remains a major cause of death by disease in children. 15,700 children are diagnosed with cancer each year in the USA.
Onyx Pharmaceuticals, Inc. today announced updated interim results of the Phase 1b dose-escalation trial, known as the 006 study, evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed and/or refractory myeloma. These data are being presented today at the 46th American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
BioCardia, Inc., focused on regenerative biologic therapies for cardiovascular disease, today announced positive results from a Phase 1/2 heart failure trial using the Company's Helical Infusion System, comprising the Helical Infusion System Catheter and Morph Vascular Access Catheter, to deliver allogeneic, or "off-the-shelf," and autologous, or from the treated patient, mesenchymal (adult) stem cells (MSCs) via transendocardial injection.
› Verified 2 days ago
Rachel Hamm, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1007 Johnstown Ave, Salina, KS 67401 Phone: 913-706-3224 Fax: 317-863-0801 | |
Erica Mann, M.S. Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2601 E Crawford St, Salina, KS 67401 Phone: 817-336-2586 | |
Emily Hoover, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1130 E Cloud St Ste C, Salina, KS 67401 Phone: 785-414-9422 | |
Jillian B Bebb, M.S. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 155 N Oakdale Ave Ste 300, Salina, KS 67401 Phone: 785-452-6063 Fax: 785-452-6056 | |
Jessica Davis, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1710 W Schilling Rd, Salina, KS 67401 Phone: 785-243-1971 | |
Alison Irene Rassette, MS Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 155 N Oakdale Ave Ste 300, Salina, KS 67401 Phone: 785-452-6054 Fax: 785-452-6056 |